Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPECTRE atorvastatin study in castration-resistant prostate cancer
ISRCTN16951765Phase 2Completed
- Sponsor
- NHS Greater Glasgow and Clyde
- Start
- Dec 2016
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of atorvastatin in castration-resistant prostate cancer (CRPC), sponsored by NHS Greater Glasgow and Clyde. Primary endpoint: PSA response rate. Started Dec 2016; status: completed.
02
Drugs
atorvastatin
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on ISRCTN16951765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN16951765.